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sidered in the statistical analysis (510 from the acampro-
sate cohort, 256 from the control group). The two
groups of the study population were comparable in terms
of sociodemographic variables. The number of abstinent
patients treated with acamprosate was 41.2% (per proto-
col analysis), only 25.4% (per protocol analysis) of all
patients in the control group were abstinent during the
study period. Although the drug costs are three times
higher in the acamprosate cohort the cost analysis re-
sulted in total costs of DM 3,026 ($1593) per patient/
year for the acamprosate group compared to DM 4,199
($2210) per patient/year in the control group, a signifi-
cant cost saving potential of DM 1,173 ($617). Hospital-
ization could be identified as the most cost-driving factor,
and was significantly higher in the control group. CON-
CLUSION: Based on the results of this study, it is sug-
gested that an initial expensive adjuvant treatment of al-
coholism leads to less cost than any other single therapy.
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OBJECTIVES: To quantify the cost-effectiveness of indi-
navir with zidovudine (ZDV) and lamivudine (3TC) com-
pared to ZDV3TC in patients with high and low base-
line viral load as cost per life-year gained (LYG) from a
third party payer perspective. METHODS: Progression
of HIV through 3 stages (CD4 200–500, CD4 200
No AIDS, AIDS) until death was modeled using a
Markov cycle tree, based on CD4 and viral load fac-
tors. Patients who failed to respond or progressed began
salvage therapy. Mortality, tolerability and disease pro-
gression rates were obtained from published sources. Six-
teen week clinical outcomes according to baseline viral
load (100,000 c/ml; 100,000 c/ml) were determined
from a randomized controlled trial (AVANTI II). Drugs
and medical care costs disaggregated by CD4 strata were
obtained from a Canadian HIV costing study. Future
costs and outcomes were discounted at 5%. RESULTS:
The incremental cost (1997 CDN $) per LYG with IDV/
ZDV/3TC vs. ZDV/3TC in patients with baseline viral
load below 100,000 c/ml was $68,353 per LYG. Indi-
navir/ZDV/3TC is more cost-effective in patients with
high baseline viral load (100,000 c/ml) at $24,852 per
LYG. The model was robust to probabilities and costs
tested in the sensitivity analysis. CONCLUSIONS: These
figures indicate that HAART therapies, such as indinavir/
ZDV/3TC provide important improvements at a reason-
able cost and thus are attractive both clinically and eco-
nomically, especially in patients with high baseline viral
load. Factors such as resistance and adherence to therapy
need to be considered in future models.
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Models of the clinical and economic impact of hyperten-
sion and the benefits of blood pressure (BP) control typi-
cally focus on either diastolic or systolic blood pressure
(DBP or SBP) but not both. For example, our previously-
reported Hypertension Burden of Illness Model consid-
ered only DBP and therefore could not address the issue
of systolic hypertension. OBJECTIVE: To estimate the
clinical and economic benefits of achieving both DBP and
SBP goals in treated hypertensives. METHODS: We re-
vised and updated our existing model which was de-
signed to forecast cardiovascular disease (CVD) incidence
and direct medical-care costs for specified populations,
such as the membership of a managed-care plan, and
simulates the effect of programs to improve BP control.
The underlying Framingham Heart Study (FHS) risk
equations, which previously quantified the relationship
between DBP and CVD risk, were replaced with new
FHS equations that incorporated both DBP and SBP. The
economic costs of CVD were estimated as in the earlier
version using major national health surveys and health-
care cost databases. RESULTS: We estimate that 9.6 mil-
lion persons aged 40–79 years in the US are treated for
hypertension but continue to have uncontrolled DBP
(90 mmHg) or SBP (140 mmHg). If all of these pa-
tients were treated to high-normal BP (140/90), an esti-
mated 414,000 CVD events would be prevented over 10
years resulting in medical care cost savings of $6.5 bil-
lion, an average of 43 events and $674,000 per 1000 pa-
tients. If such treatment were limited to patients with a
history of CVD, it would prevent an estimated 59 events
and save $761,000 per 1000 patients. CONCLUSION:
